Serum Anticardiolipin, anti-beta2 glycoprotein I and Lupus Anticoagulant in Women Experiencing Recurrent Pregnancy Loss: A case- control study in Iraqis pregnant women

Noora Majed Kadhium AL-Shukr

doi:10.51699/cajmns.v7i2.3138

Authors

Noora Majed Kadhium AL-Shukr University of AL-Qadisiyah college of medicine

DOI:

https://doi.org/10.51699/cajmns.v7i2.3138

Keywords:

Anticardiolipin, Anti-beta2 glycoprotein, Recurrent pregnancy loss, Antiphospholipid syndrome

Abstract

The current study was designed to compare the prevalence of anticardiolipin and anti-beta2 glycoprotein I IgG and IgM antibody levels in married women who have repeated miscarriage and had been diagnosed of recurrent pregnancy loss and normotensive women. A total of 120 women with recurrent pregnancy loss RPL and 120 normotensive married women who didn’t have any pregnancy complications and were tested for both IgM and IgG for anti-cardiolipin and anti-beta2 glycoprotien 1 antibodies, and aPTT. The findings revealed that the level of both IgM and IgG for anti-cardiolipin and anti-beta2 glycoprotien 1 antibodies were significantly higher than normal standards were examined in 120 women with repeated miscarriages and matched with 120 normal healthy women, the age range of patients from 21-43 (mean age was 32.1); were matched with 120 healthy married women of the same age range (21-43) with no complications (mean age 31.8). In conclusion, women with recurrent pregnancy loss exhibited increased anticardiolipin and anti-beta 2 glycoprotein antibodies when compared to the healthy control group. However, future researches in chromosomal abnormality and HLA gene that might cause repeat incidences of miscarriage.

References

Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, et al., “ESHRE guideline: recurrent pregnancy loss,” Hum Reprod Open, 2018;2018:hoy004.

Practice Committee of the American Society for Reproductive Medicine, “Definitions of infertility and recurrent pregnancy loss: a committee opinion,” Fertil Steril, 2013;99:63.

Jauniaux E, Farquharson RG, Christiansen OB, Exalto N, “Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage,” Hum Reprod, 2006;21:2216–22.

Rai R, Regan L, “Recurrent miscarriage,” Lancet, 2006;368:601–11.

du Fosse NA, van der Hoorn MP, van Lith JMM, le Cessie S, Lashley EELO, “Advanced paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis,” Hum Reprod Update, 2020;26:650–69.

du Fosse N, van der Hoorn ML, Eikmans M, Heidt S, le Cessie S, Mulders A, et al., “Evaluating the role of paternal factors in aetiology and prognosis of recurrent pregnancy loss: study protocol for a hospital-based multicentre case-control study and cohort study (REMI III project),” BMJ Open, 2019;9:e033095.

du Fosse NA, van der Hoorn ML, Buisman NH, van Lith JMM, le Cessie S, Lashley EELO, “Paternal smoking is associated with an increased risk of pregnancy loss in a dose-dependent manner: a systematic review and meta-analysis,” FS Rev, 2021;2:227–38.

McQueen DB, Zhang J, Robins JC, “Sperm DNA fragmentation and recurrent pregnancy loss: a systematic review and meta-analysis,” Fertil Steril, 2019;112:54–60.e3.

Nybo Andersen AM, Hansen KD, Andersen PK, Davey Smith G, “Advanced paternal age and risk of fetal death: a cohort study,” Am J Epidemiol, 2004;160:1214–22.

Venners SA, Wang X, Chen C, Wang L, Chen D, Guang W, et al., “Paternal smoking and pregnancy loss: a prospective study using a biomarker of pregnancy,” Am J Epidemiol, 2004;159:993–1001.

Jaslow CR, Carney JL, Kutteh WH, “Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses,” Fertil Steril, 2010;93:1234–43.

Stephenson MD, “Frequency of factors associated with habitual abortion in 197 couples,” Fertil Steril, 1996;66:24–9.

Youssef A, Lashley L, Dieben S, Verburg H, van der Hoorn ML, “Defining recurrent pregnancy loss: associated factors and prognosis in couples with two versus three or more pregnancy losses,” Reprod Biomed Online, 2020;41:679–85.

Liddell HS, Pattison NS, Zanderigo A, “Recurrent miscarriage–outcome after supportive care in early pregnancy,” Aust N Z J Obstet Gynaecol, 1991;31:320–2.

Youssef A, Vermeulen N, Lashley EELO, Goddijn M, van der Hoorn MLP, “Comparison and appraisal of (inter)national recurrent pregnancy loss guidelines,” Reprod Biomed Online, 2019;39:497–503.

Brigham SA, Conlon C, Farquharson RG, “A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage,” Hum Reprod, 1999;14:2868–71.

Lund M, Kamper-Jorgensen M, Nielsen HS, Lidegaard O, Andersen AM, Christiansen OB, “Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success?” Obstet Gynecol, 2012;119:37–43.

Steyerberg EW, Harrell FE Jr., “Prediction models need appropriate internal, internal-external, and external validation,” J Clin Epidemiol, 2016;69:245–7.

Collins GS, Reitsma JB, Altman DG, Moons KG, “Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement,” BMC Med, 2015;13:1.

Collins GS, Reitsma JB, Altman DG, Moons KG, “Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD),” Ann Intern Med, 2015;162:735–6.

Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al., “PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration,” Ann Intern Med, 2019;170:W1–33.

Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al., “PROBAST: a tool to assess the risk of bias and applicability of prediction model studies,” Ann Intern Med, 2019;170:51–8.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” Open Med, 2009;3:e123–30.

Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, et al., “Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement,” BMC Med, 2018;16:120.

de Laat B, Derksen RH, Urbanus RT, de Groot PG, “IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis,” Blood, 2005;105(4):1540–1545.

Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D, “The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature,” Arthritis Care Res, 2013;65(11):1869–1873.

Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG, “Update of the guidelines for lupus anticoagulant detection,” J Thromb Haemost, 2009;7(10):1737–1740.

Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al., “Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis,” J Thromb Haemost, 2020;18(11):2828–2839.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al., “EULAR recommendations for the management of antiphospholipid syndrome in adults,” Ann Rheum Dis, 2019;78(10):1296–1304.